G.F.C Green Fields Capital Ltd.

TASE:GFC-M Stock Report

Market Cap: ₪115.4m

G.F.C Green Fields Capital Valuation

Is GFC-M undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GFC-M when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GFC-M (₪11.5) is trading below our estimate of fair value (₪36.67)

Significantly Below Fair Value: GFC-M is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GFC-M?

Key metric: As GFC-M is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GFC-M. This is calculated by dividing GFC-M's market cap by their current earnings.
What is GFC-M's PE Ratio?
PE Ratio5.4x
Earnings₪21.34m
Market Cap₪115.44m

Price to Earnings Ratio vs Peers

How does GFC-M's PE Ratio compare to its peers?

The above table shows the PE ratio for GFC-M vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average20.1x
KMDA Kamada
21.6x16.1%₪1.3b
REKA Rekah Pharmaceutical Industry
23.8xn/a₪162.3m
MBX Microbix Biosystems
8xn/aCA$40.7m
ALGEN genOway Société anonyme
27xn/a€33.9m
GFC-M G.F.C Green Fields Capital
5.4xn/a₪115.4m

Price-To-Earnings vs Peers: GFC-M is good value based on its Price-To-Earnings Ratio (5.4x) compared to the peer average (20.1x).

Price to Earnings Ratio vs Industry

How does GFC-M's PE Ratio compare vs other companies in the Asian Biotechs Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
GFC-M 5.4xIndustry Avg. 32.7xNo. of Companies10PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GFC-M is good value based on its Price-To-Earnings Ratio (5.4x) compared to the Asian Biotechs industry average (32.7x).

Price to Earnings Ratio vs Fair Ratio

What is GFC-M's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GFC-M PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio5.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate GFC-M's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Evogene

₪32.5m

Operates as a computational biology company.

EVGN

₪6.07

7D

-10.8%

1Y

-72.3%

Protalix BioTherapeutics

US$112.5m

A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.

PLX

US$7.33

7D

-0.1%

1Y

97.5%